Efficacy and safety of ticagrelor monotherapy following a brief DAPT vs. prolonged 12-month DAPT in ACS patients post-PCI: a meta-analysis of RCTs.
Background: As per current guidelines, acute coronary syndrome (ACS) patients who undergo percutaneous coronary intervention (PCI) should be started on dual antiplatelet therapy (DAPT) for a period of 12 months. Objective: To assess the efficacy and safety of brief DAPT (up to 3 months) succeeded by...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 80; no. 12; pp. 1871 - 1883 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Springer Nature
Dec2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182280334&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 182280334 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Dec2024 vid: 80 iid: 12 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 182280334 179588408 182280334 182280334 10.1007/s00228-024-03747-w 182280334 ppf: 1871 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Efficacy and safety of ticagrelor monotherapy following a brief DAPT vs. prolonged 12-month DAPT in ACS patients post-PCI: a meta-analysis of RCTs. aug: au: Qamar, Usama Naeem, Farhan Maqsood, Muhammad Talha Khan, Maleeka Zamurad Imtiaz, Zeeshan Saeed, Fatima Gupta, Neelesh Brohi, Fnu Zafarullah Mkpozi, Celestine Sattar, Yasar affil: https://ror.org/02rrbpf42 Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan sug: subj: Acute Coronary Syndrome Drug Therapy Adenosine Triphosphate Therapeutic Use Dual Antiplatelet Therapy Percutaneous Coronary Intervention Treatment Duration Drug Efficacy Evaluation Patient Safety Evaluation Human Systematic Review Meta Analysis Cochrane Library Embase PubMed Cardiac Patients Major Adverse Cardiac Events Prevention and Control Stroke Prevention and Control Ischemia Prevention and Control Hemorrhage Prevention and Control Incidence Adverse Health Care Event Prevention and Control Odds Ratio Confidence Intervals Descriptive Statistics ab: Background: As per current guidelines, acute coronary syndrome (ACS) patients who undergo percutaneous coronary intervention (PCI) should be started on dual antiplatelet therapy (DAPT) for a period of 12 months. Objective: To assess the efficacy and safety of brief DAPT (up to 3 months) succeeded by ticagrelor monotherapy compared with a 12-month DAPT in ACS patients following PCI. Methods: We systematically searched Cochrane, Embase, and PubMed to find relevant randomized clinical trials. Examined outcomes included the incidence of major adverse cerebrovascular and cardiovascular events (MACCE), bleeding events, and the composite incidence of net adverse clinical events (NACE). Results: Our primary analysis included 21,927 ACS patients from six RCTs. Our pooled results indicate that following PCI in individuals with ACS, brief DAPT followed by ticagrelor did not increase the risk of MACCE (OR 0.92, 95% CI 0.79–1.07) but significantly reduced the risk of minor or major bleeding (OR 0.52, 95% CI 0.44–0.62) and NACE (OR 0.71, 95% CI 0.59–0.86) compared with a long-term DAPT within a follow-up of 12 months. Conclusion: Brief DAPT followed by ticagrelor monotherapy is superior to a 12-month DAPT in offering a net clinical advantage in ACS patients following PCI. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|